PAD (peripheral arterial disease) device co closes $25m series B:
This article was originally published in Clinica
Pathway Medical Technologies, the Redmond, Washington-based developer of the Pathway Atherectomy system for treating peripheral arterial disease (PAD), welcomed two new shareholders this week, following the completion of a $25m series B financing. HLM Venture Partners (Boston, Massachusetts) led the round and Latterell Venture Partners (San Francisco, California) participated together with existing investors ABN AMRO Capital Lifesciences, Giza Ventures and Oxford Bioscience.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.